Bente Lund

20002019
Hvis du har foretaget ændringer i Pure, vil de snart blive vist her.

Publikationer 2000 2019

  • 19 Tidsskriftartikel
  • 13 Konferenceabstrakt i tidsskrift
  • 2 Poster
  • 1 Konferenceartikel i tidsskrift
Filter
Konferenceabstrakt i tidsskrift
2018

A time without symptoms or toxicity analysis of niraparib compared with routine surveillance in the maintenance treatment of patients with recurrent ovarian cancer

Mirza, M. R., Walder, L., Monk, B. J., Tinker, A. V., Mahner, S., Gil-Martin, M., Kalbacher, E., Waters, J., Wenham, R. M., Malander, S., Gilbert, L., Sehouli, J., Casado Herraez, A., Hardy-Bessard, A., Williams, S. J., Rimel, B. J., Lund, B., Levy, T., Guy, H. & Matulonis, U. A., okt. 2018, I : Value in Health. 21, Suppl. 3, s. S16 PCN7.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2017

Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial

Oza, A. M., Matulonis, U. A., Malander, S., Sehouli, J., del Campo, J. M., Berthon-Rigaud, D., Banerjee, S., Scambia, G., Berek, J. S., Lund, B., Tinker, A. V., Hilpert, F., Palacio Vázquez, I., D’hondt, V., Benigno, B., Provencher, D. M., Buscema, J., Hudgens, S., Agarwal, S. & Mirza, M. R., 2017, I : Annals of Oncology. 28, Suppl. 5, s. 330 1 s., 930O.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Åben adgang
2016

An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

Haslund, C., Muhic, A., Lukacova, S., Lund, B., Lassen-Ramshad, Y., Meyer, M., Roland, M. & Poulsen, H. S., 1 okt. 2016, I : Neuro-Oncology. 18, s. iv6 1 s.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)

Crochiere, M., Vergote, I. B., Lund, B., Havsteen, H., Ujmajuridze, Z., Van Nieuwenhuysen, E., Haslund, C., Juhler-Nottrup, T., Mau-Sorensen, M., Berteloot, P., Kranich, A. L., Meade, J., Wright, G., Shacham, E., Rashal, T., Saint-Martin, J-R., Shacham, S., Kauffman, M., Mirza, M. R. & Landesman, Y., 2016, I : Annals of Oncology. 27, Suppl. 6, 886P.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

1 Citation (Scopus)

Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

Vergote, I., Lund, B., Havsteen, H., Ujmajuridze, Z., Van Nieuwenhuysen, E., Haslund, C., Juhler-Nottrup, T., Neven, P., Mau-Sorensen, M., Berteloot, P., Kranich, A. L., Rashal, T., Meade, J., Landesman, Y., Saint-Martin, J-R., Wright, G., Crochiere, M., Shacham, S., Kauffman, M. & Mirza, M. R., 2016, I : Annals of Oncology. 27, Suppl. 6, 8540O.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2015

Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers

Vergote, I., Lund, B., Havsteen, H., Ujmajuridze, Z., Leunen, K., Haslund, C. A., Juhler-Nøttrup, T., Roed, H., Rashal, T., Kranich, A. L., Landesman, Y., Saint-Martin, J-R., Carlson, R., Shacham, S., Kauffman, M. & Mirza, M. R., 2015, I : Journal of Clinical Oncology. 33, 15 Suppl., TPS5565.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Cell Nucleus Active Transport
Neoplasms
Colorectal Neoplasms
KPT-330
Survival
2014

Disease relapse in ovarian cancer patients detected by HE4 and CA125

Steffensen, K. D., Waldstrøm, M., Brandslund, I., Lund, B., Sørensen, S. M., Petzold, M. & Jakobsen, A., 2014, I : International Journal of Gynecological Cancer. 29, 9, 4 suppl., s. 189

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

KCP-330-005/SIGN: A phase II, open-label study of efficacy and safety of the selective inhibitor of nuclear export (SINE) KPT-330 (SELINEXOR) in patients with advanced gynaecologic malignancies

Vergote, I., Lund, B., Ujmajuridze, Z., Havsteen, H., Rashal, T., McCartney, J., Kauffman, M., Shacham, S. & Mirza, M. R., 2014, I : International Journal of Gynecological Cancer. 29, 9, 4 suppl., s. 1182

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2012

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Steffensen, K. D., Waldstrom, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B. & Jakobsen, A. K. M., 20 maj 2012, I : Journal of Clinical Oncology. 30, 15

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

2011
2010

Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial

Brundage, M., Gropp, M., Mefti, F., Mann, M. K., Lund, B., Gebeski, V., Wolfram, G., Reed, N., Pignata, S. & Ferrero, A., 20 maj 2010, I : Journal of Clinical Oncology. 28, 15, 5044.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

Steffensen, K. D., Waldstrøm, M., Lund, B., Bergfeldt, K., Keldsen, N., Marth, C., Vergote, I. B. & Jakobsen, A. K., 2010, I : Journal of Clinical Oncology. 28, 15suppl, TPS254.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Platinum
Ovarian Neoplasms
Combination Drug Therapy
Epidermal Growth Factor Receptor
Neoplasms
2006

Pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) in combination in the salvage treatment of epithelial ovarian cancer (OC)—a Danish Gynaecologic Cancer Group (DGC) study

Mirza, M. R., Lund, B., Bertelsen, K., Lindegaard, J., Keldsen, N., Mellemgaard, A. & Depont, R., 20 jun. 2006, I : Journal of Clinical Oncology. 24, 18_suppl, 1 s., 5094.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review